Telomir Pharmaceuticals (NASDAQ:TELO) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) posted its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07, FiscalAI reports.

Telomir Pharmaceuticals Stock Performance

Shares of NASDAQ TELO opened at $0.71 on Friday. The firm’s 50 day moving average price is $1.10 and its 200-day moving average price is $1.21. The company has a market cap of $52.32 million, a PE ratio of -0.80 and a beta of -0.19. Telomir Pharmaceuticals has a 52-week low of $0.69 and a 52-week high of $1.58.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on TELO shares. Maxim Group started coverage on Telomir Pharmaceuticals in a report on Thursday, September 17th. They issued a “buy” rating and a $4.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Telomir Pharmaceuticals during the second quarter valued at $359,000. OneDigital Investment Advisors LLC purchased a new stake in shares of Telomir Pharmaceuticals during the second quarter valued at $29,000. Finally, Bank of New York Mellon Corp bought a new stake in Telomir Pharmaceuticals in the 2nd quarter worth about $66,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc is a development-stage biotechnology company focused on therapies intended to address age-related diseases and conditions. The company’s research is centered on telomere biology, a field involving the protective DNA sequences at the ends of chromosomes that are associated with cellular aging.

Telomir’s lead investigational product is TELOMIR-1, an orally administered small-molecule compound being developed to promote telomere lengthening and support cellular health.